Evidence map›Paper›PMID 40328994›Full record

ArticleAnnals of intensive care2025

Nosocomial lower respiratory tract infections in patients with immunosuppression: a cohort study.

Luis Felipe Reyes, Natalia Sanabria-Herrera, Saad Nseir, Otavio T Ranzani, Pedro Povoa, Emilio Diaz, Marcus J Schultz, Alejandro Rodríguez, Cristian C Serrano-Mayorga, Gennaro De Pascale and 29 more

Abstract read
In one paragraph

Article in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Observational
  2. Pneumonia after Solid Organ Transplantation.Seminars in respiratory and critical care medicine · 2026
    Review
  3. ICU-acquired infection in neutropenic patients.Critical care (London, England) · 2026
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Luis Felipe Reyes *Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chia, Colombia. luis.reyes5@unisabana.edu.co.
Natalia Sanabria-Herrera *Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chia, Colombia.
Saad NseirUniversity Hospital of Lille, Lille, France.
Otavio T RanzaniBarcelona Institute for Global Health, ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Pedro PovoaNOVA Medical School, NOVA University of Lisbon, Lisbon, Portugal.
Emilio DiazCorporacio Sanitaria Parc Tauli, Sabadell, Spain.
Marcus J SchultzIntensive Care, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Alejandro RodríguezHospital Joan XXIII de Tarragona, Tarragona, Spain.
Cristian C Serrano-MayorgaUnisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chia, Colombia.
Gennaro De PascaleDepartment of Intensive Care and Anesthesiology, Fondazione Policlinico Universitario A. Gemelli IRCCS Rome, Rome, Italy.
Paolo NavalesiMagna Graecia University, Catanzaro, Italy.
Szymon SkoczynskiDepartment of Lung Diseases and Tuberculosis, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Mariano EsperattiHospital Privado de Comunidad, Escuela Superior de Medicina, Universidad Nacional de Mar del Plata, Mar del Plata, Argentina.
Luis Miguel CoelhoHospital de Sao Francisco Xavier, Lisbon, Portugal.
Andrea CortegianiDepartment of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, Palermo, Italy.
Stefano AlibertiMedical University of Silesia, Katowise, Poland.
Anselmo CaricatoDepartment of Intensive Care and Anesthesiology, Fondazione Policlinico Universitario A. Gemelli IRCCS Rome, Rome, Italy.
Helmut J F SalzerDivision of Infectious Diseases and Tropical Medicine, Department of Internal Medicine 4 - Pneumology, Kepler University Hospital, Linz, Austria.
Adrian CeccatoCritical Care Center, Hospital Universitari Parc Taulí, Institut d'Investigació I Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain.
Rok CivljakUniversity of Zagreb School of Medicine, Zagreb, Croatia.
Paolo Maurizio SoaveDepartment of Intensive Care and Anesthesiology, Fondazione Policlinico Universitario A. Gemelli IRCCS Rome, Rome, Italy.
Charles-Edouard LuytSorbonne Université, Service de Médecine Intensive Réanimation, Groupe Hospitalier Pitié-Salpêtriere, Assistance Publique-Hôpitaux de Paris, Paris, France.
Pervin Korkmaz EkrenEge University Medical Faculty, Izmir, Turkey.
Fernando RiosHospital Nacional Alejandro Posadas, Buenos Aires, Argentina.
Joan Ramon MasclansCritical Care Department, Hospital del Mar, GREPAC, Hospital del Mar Research Institute, MELIS, Universitat Pompeu Fabra, Barcelona, Spain.
Judith MarinHospital del Mar, Barcelona, Spain.
Silvia Iglesias-MolesHospital Arnau de Vilanova de Lleida, Lleida, Spain.
Stefano NavaAlma Mater Studiorum, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138, Bologna, Italy.
Davide ChiumelloASST Santi Paolo e Carlo, Milan, Italy.
Lieuwe D J BosIntensive Care, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Antonio ArtigasIntensive Care Medicine Department, Corporacion Sanitaria Universitaria Parc Tauli, Institut d´Investigació I Innovació Parc Tauli I3PT, CIBER Enfermedades Respiratorias, Autonomous University of Barcelona, Sabadell, Spain.
Filipe FroesChest Department, Hospital Pulido Valente, CHULN, Lisbon, Portugal.
David GrimaldiHopital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Mauro PanigadaAnesthesia and Critical Care, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Fabio Silvio TacconeHopital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Massimo AntonelliDepartment of Intensive Care and Anesthesiology, Fondazione Policlinico Universitario A. Gemelli IRCCS Rome, Rome, Italy.
Antoni TorresHospital Clinic of Barcelona, Barcelona, Spain.
Ignacio Martin-LoechesJames's University Hospital, Trinity College, Dublin 8, D08 NHY, Ireland.ORCID http://orcid.org/0000-0002-5834-4063
European Network for ICU-Related Respiratory Infections (ENIRRIs) European Respiratory Society-Clinical Research Collaboration Investigators

Funding

Irish Research eLibrary MED-244-2018
6 · The paper itself

Abstract

backgroundThis post-hoc analysis of a multinational, multicenter study aimed to describe and compare clinical characteristics, microbiology, and outcomes between immunosuppressed and non-immunosuppressed patients with nosocomial lower respiratory tract infections (nLRTI). The study utilized data from the European Network for ICU-related Respiratory Infections, including 1,060 adult ICU patients diagnosed with nLRTI. Descriptive statistics were used to compare baseline characteristics and pathogen distribution between groups. A Cox proportional hazards model stratified by immunosuppression status was applied to assess 28-day mortality risk, adjusting for disease severity and key clinical variables.

resultsImmunosuppression was observed in 24.9% (264/1060) of the patients, and oncological conditions were the most common etiology of immunosuppression. Chronic pulmonary and cardiovascular diseases were the most frequent comorbidities. In both groups, Pseudomonas aeruginosa was the predominant microorganism, particularly affecting patients with immunosuppression (25.3% vs. 16.7%, p = 0.032). Cox regression model adjusted for disease severity (SAPS II), polytraumatized status, altered consciousness, and postoperative status, SAPS II remained a strong independent predictor of mortality, with each one-point increase associated with a 2.3% higher risk of death (HR: 1.023, 95% CI 1.017-1.030, p < 0.001). The analysis also revealed significant heterogeneity in mortality risk among immunosuppressed patients, with hematological malignancies, recent chemotherapy, and bone marrow transplantation associated with the highest mortality.

conclusionsImmunosuppressed patients had a lower adjusted survival probability compared to non-immunosuppressed patients. Moreover, P. aeruginosa was the most frequently identified etiological pathogen in immunosuppressed patients.

Indexed as

Critical careImmunosuppressionNosocomial lower respiratory tract infections

Identifiers

PMID40328994
PMCPMC12055687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.